ArticleCancer causes & control : CCC2026
Epidemiology of esophageal cancer in Xiamen, China, 2011-2020: trends in incidence, mortality, and survival from a population-based registry study.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal cancer remains a major public health concern, yet data on its long-term burden in Xiamen, China, are limited. This study assessed incidence, mortality, survival rates, and their temporal trends from 2011 to 2020.
methodsPopulation-based cancer registry data were analyzed for all newly diagnosed esophageal cancer cases in Xiamen between 2011 and 2020, with follow-up through September 2023. Age-standardized incidence and mortality rates (ASIR, ASMR) were calculated using Segi's world population. Relative survival (RS) and age-standardized relative survival (ARS) were estimated using registry follow-up data. Trends were evaluated using Joinpoint regression.
resultsA total of 5,318 incident cases and 4,445 deaths were recorded. The ASIR and ASMR were 18.96 and 15.61 per 100,000, respectively, with significantly higher rates in males and in rural areas. Both incidence (AAPC = - 4.20%, p = 0.001) and mortality (AAPC = - 5.07%, p = 0.024) declined over the study period. The 5-year ARS was 19.2% (95% CI 17.9-20.5%), higher in females than males (28.2% vs. 17.7%), but comparable between urban and rural residents. Yearly survival rates fluctuated without a significant upward trend.
conclusionsFrom 2011 to 2020, esophageal cancer incidence and mortality in Xiamen declined, but survival rates remained low. The persistent burden highlights the need for strengthened prevention, early detection, and cost-effective treatment strategies, particularly for high-risk populations.
Indexed as
Identifiers
41931127What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.